This study from the Centers for Disease Control and Prevention (CDC) finds disparate monoclonal antibody (mAb) treatment of COVID-19 in Hispanic, Black, Asian, and Other race patients, compared to non-Hispanic and White patients. Differences in treatment with dexamethasone and remdesivir were less apparent.
Analyzing data from 41 healthcare systems in the National Patient-Centered Clinical Research Network, the researchers found that among all patients with a positive COVID-19 test (805,276):
The researchers also found that among inpatients:
Equitable receipt of treatments, such as mAb and antiviral medications, and implementation of prevention practices are essential to reducing racial and ethnic inequities in COVID-19-associated illnesses and deaths, the researchers say.Read More >>